Understanding how LAG3 affects immune responses in cancer and autoimmune diseases
Structure, Function and Mechanistic Analysis of LAG3
This study is looking at a protein called LAG3 that affects how our immune cells work, especially in cancer and long-lasting infections, to help create better treatments for patients with conditions like metastatic melanoma and autoimmune diseases.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project ID | NIH-11041132 on NIH RePORTER |
What this research studies
This research investigates the role of LAG3, an inhibitory receptor that regulates T cell activity, particularly in the context of cancer and chronic infections. By analyzing how LAG3 functions and its interactions with other immune signals, the study aims to develop better immunotherapies that can either block or enhance LAG3's effects. Patients may benefit from insights gained in this research, which could lead to more effective treatments for conditions like metastatic melanoma and autoimmune diseases. The research employs a combination of laboratory experiments and in vivo models to explore these mechanisms.
Who could benefit from this research
Good fit: Ideal candidates for participation or benefit from this research include patients with metastatic melanoma or those suffering from autoimmune diseases.
Not a fit: Patients with conditions unrelated to immune modulation or those not responding to current immunotherapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective immunotherapies for cancer and autoimmune diseases.
How similar studies have performed: Previous research has shown promise in targeting LAG3 for cancer treatment, indicating a potential for success in this area.
Where this research is happening
Pittsburgh, United States
- University of Pittsburgh at Pittsburgh — Pittsburgh, United States (Active)
Researchers
- Principal investigator: Vignali, Dario Aa — University of Pittsburgh at Pittsburgh
- Study coordinator: Vignali, Dario Aa
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.